

**OVUGEL- triptorelin acetate gel**  
**Aurora Pharmaceutical, Inc.**

---

**OvuGel®**

**ACTIVE INGREDIENT:**

triptorelin acetate

**DOSAGE FORM & STRENGTH:**

100 mcg triptorelin per mL (as triptorelin acetate)  
Gel for intravaginal use

**INDICATIONS FOR USE:**

For the synchronization of time of insemination in weaned sows to facilitate a single fixed-time artificial insemination. Not approved for use in gilts. Safety and effectiveness have not been evaluated in these animals.

**DESCRIPTION:**

OvuGel® is a thin, clear to slightly hazy gel. Each mL of OvuGel® contains 100 mcg of triptorelin (as triptorelin acetate) for intravaginal administration.

**WARNINGS:**

**WITHDRAWAL PERIOD:**

No withdrawal period is required when used according to labeling.

**USER SAFETY WARNINGS:**

Not for Use in Humans. Keep Out of Reach of Children. The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information.

**ANIMAL SAFETY WARNINGS:**

OvuGel® should not be used in sows with obvious reproductive tract abnormalities.

**RECOMMENDATIONS FOR SAFE AND EFFECTIVE USE:**

Use of a bottle mount multi-dose applicator is recommended to ensure accurate dosing. The use of adequate sperm numbers per insemination and proper semen storage, as recommended by the semen or artificial inseminator catheter suppliers, is recommended.

## **DIRECTIONS FOR USE:**

OvuGel® should be administered intravaginally at approximately 96 hours after weaning. The product should be warmed at room temperature for a minimum of 10 minutes prior to use. Insert the delivery tube into the vagina so that the tip rests 1/2 inch (1-3 cm) posterior to the cervix. Use a separate sheath over the delivery tube for each sow treated. Each sow should receive a single 2 mL dose of OvuGel®. Sows should be inseminated 22 +/- 2 hours following administration of OvuGel® using standard artificial insemination techniques. Sows should be exposed to a boar during time of insemination. (See end of package insert for more detailed directions for OvuGel® administration).

## **STORAGE, HANDLING, AND DISPOSAL:**

Store at refrigerator temperature 36-46°F (2-8°C). Excursions permitted to 77°F (25°C) for no more than 5 days during shipping.

OvuGel® should be administered within 1 hour of warming; unused portions may be refrigerated immediately after use. The bottle stopper may be punctured a maximum of three times. Discard 28 days after the stopper is first punctured.

## **HOW SUPPLIED:**

OvuGel® is available in 52.5 mL multi-dose bottle.

## **QUESTIONS/COMMENTS**

To obtain an MSDS, for technical assistance, or to report adverse events, contact Aurora Pharmaceutical at 1-888-215-1256 or [www.aurorapharmaceutical.com](http://www.aurorapharmaceutical.com). For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or [www.fda.gov/reportanimalae](http://www.fda.gov/reportanimalae).

Approved by FDA under NADA #141-339

NDC 51072-087-00

## **Principal Display Panel - 52.5 mL Bottle Carton**

OvuGel®

(triptorelin acetate)

100 mcg triptorelin per mL (as triptorelin acetate)

Gel for intravaginal use

## **INDICATIONS FOR USE:**

For the synchronization of time of insemination in weaned sows to facilitate a single fixed-time artificial insemination.

Not approved for use in gilts. Safety and effectiveness have not been evaluated in these animals.

Net Contents: 52.5 mL

multi-dose bottle (26 doses, 2 mL each)

Approved by FDA under NADA # 141-339

NDC 51072-087-00

Manufactured by: Aurora Pharmaceutical, Inc.  
1196 Hwy 3 S  
Northfield, MN 55057

IN 40-1859 Rev. 02/2025  
Reorder No: 59030



## OVUGEL

triptorelin acetate gel

### Product Information

Product Type	OTC ANIMAL DRUG	Item Code (Source)	NDC:51072-087
Route of Administration	VAGINAL		

**Active Ingredient/Active Moiety**

<b>Ingredient Name</b>		<b>Basis of Strength</b>	<b>Strength</b>
<b>Triptorelin Acetate</b> (UNII: 430FW291R9) (Triptorelin - UNII:9081Y98W2V)		Triptorelin	100 ug in 1 mL

**Packaging**

#	<b>Item Code</b>	<b>Package Description</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
1	NDC:51072-087-00	1 in 1 CARTON		
1		52.5 mL in 1 BOTTLE		

**Marketing Information**

<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
NADA	NADA141339	01/20/2026	

**Labeler** - Aurora Pharmaceutical, Inc. (832848639)**Establishment**

<b>Name</b>	<b>Address</b>	<b>ID/FEI</b>	<b>Business Operations</b>
Aurora Pharmaceutical, Inc.		832848639	manufacture

Revised: 1/2026

Aurora Pharmaceutical, Inc.